Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease

摘要

AimsWe have previously shown that the systemic exposure to inhaled fluticasone propionate (FP) is reduced in asthmatics compared with healthy subjects. We have now compared its pharmacokinetics in patients suffering from chronic obstructive pulmonary disease (COPD, n = 10) and matched healthy subjects (n = 13).